Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced an interview with President and CEO Dr. James A. Hayward conducted by the BBC’s Business Daily as part of an episode titled ‘Tracing cotton’s DNA’. The episode is available at https://www.bbc.co.uk/sounds/play/w3ct1jn9.
CertainT® for Cotton Traceability
CertainT, Applied DNA’s traceability platform, provides an approach to authenticate goods within large and complex supply chains for materials such as cotton, and leather, home textiles and apparel, pharmaceuticals and nutraceuticals, personal care, cannabis, and other products. To date, CertainT has ensured the authenticity of approximately 300 million pounds of North American Pima and Upland cotton and has been deployed to secure Egyptian and Australian cotton.
CertainT begins by authenticating the fiber content in cotton to confirm its origin. The platform then employs a unique molecular identifier produced by the Company’s LinearDNA™ platform to mark cotton fibers in bulk. The cotton fiber is then tested for the presence of the identifier via the Company’s proprietary, portable readers as the cotton fiber travels throughout a global supply chain and is converted into yarn, fabric, and finished goods. The detection of the identifier confirms origin and authenticity; its absence can signal for blending with illicit cotton, including cotton potentially produced by means of forced labor. The CertainT logo signifies to consumers of cotton products that they can trust the products they are buying with said trust grounded in forensic, science-based authentication. Consumers can therefore be confident in the knowledge that Brands and their supply chains have taken the necessary steps to assure that the cotton product itself is authentic and sustainably and responsibly sourced from a known origin.
About Applied DNA Sciences
Applied DNA is commercializing LinearDNA™, its proprietary, large-scale polymerase chain reaction (“PCR”)-based manufacturing platform that allows for the large-scale production of specific DNA sequences.
The LinearDNA platform has utility in the nucleic acid-based in vitro diagnostics and preclinical nucleic acid-based drug development and manufacturing market. The platform is used to manufacture DNA for customers as components of in vitro diagnostic tests and for preclinical nucleic acid-based drug development in the fields of adoptive cell therapies (CAR T and TCR therapies), DNA vaccines (anti-viral and cancer), RNA therapies, clustered regularly interspaced short palindromic repeats (CRISPR) based therapies, and gene therapies. Applied DNA has also established a COVID-19 diagnostic and testing offering that is in the early stages of commercialization and is grounded in the Company’s deep expertise in DNA.
The LinearDNA platform also has non-biologic applications, such as supply chain security, anti-counterfeiting and anti-theft technology. Key end-markets include textiles, pharmaceuticals and nutraceuticals, and cannabis, among others.
The Company’s common stock is listed on NASDAQ under ticker symbol ‘APDN,’ and its publicly traded warrants are listed on OTC under ticker symbol ‘APPDW.’
Applied DNA is a member of the Russell Microcap® Index.
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to, its history of net losses, limited financial resources, limited market acceptance, the uncertainties inherent in research and development, our ability to successfully enter into commercial contracts for the implementation of our CertainT® platform, disruptions in the supply of raw materials and supplies, and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 17, 2020 and our subsequent quarterly reports on Form 10-Q filed on February 11, 2021, and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.
Investor contact: Sanjay M. Hurry, Applied DNA Sciences, 917-733-5573, firstname.lastname@example.org
Program contact: MeiLin Wan, Applied DNA Sciences, 631-240-8849, email@example.com